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Targeted screening of EGFR compounds has become one of the medical research focuses for tumor 
therapy. A431, which naturally expresses high levels of EGFR, was compared with the stably high 
expressing EGFR cell line HEK293. Flow cytometry was used to analyze cell growth and Western blot 
was used to determine expression of EGFR, p-EGFR and p-ERK. Cellular membrane chromatography 
analysis revealed longer on-peak chromatographic and greater on-peak area of A431. Results 
demonstrated that the high-expression EGFR cell line A431 improved sensitivity of cellular membrane 
chromatography when screening drugs targeted to EGFR. 
 





The human epidermal growth factor receptor (EGFR) is a 
170-kDa transmembrane glycoprotein with an extracellular 
domain that binds EGF, TGF-, amphiregulin, betacellulin, 
heparin-binding EGF and epiregulin (EPR) (Pinaki et al., 
2007). It is one of the best characterized targets of 
cancer cells and plays an important role in regulating 
cellular proliferation, differentiation and survival of normal 
epithelial tissues. EGFR belongs to the ErbB/HER family, 
along with HER2 (ErbB2/neu), HER3 (ErbB3) and HER4 
(ErbB4). EGFR has a cytoplasmic domain with intrinsic 
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autophosphorylation and the formation of homo- or 
hetero-dimers with other members of the family. Receptor 
phosphorylation mediates activation of the mitogen-
activated protein kinase (MAPK), phosphatidylinositol 3 
kinase (PI3 kinase)/AKT, phospholipase C gamma (PLC-
)/protein kinase C (PKC), and the signal transducer and 
activator of transcription (STAT) pathways, which regulate 
cell transformation, proliferation, and survival (Cao et al., 
2008; Yarden et al., 2001). 
Previous studies demonstrated that EGFR over-
expression in tumors often correlates with poor prognosis 
and resistance to therapy (Newby et al., 1997). Common 
cancer-related EGFR alterations include overexpression, 
mutation/truncation and activation by excessive autocrine 
growth factor expression or heterodimerization with other 
ErbB family members. EGFR deregulation contributes to 
proliferation, transformation, angiogenesis, invasion, 
metastasis and inhibition of apoptosis in cancer cells 
(Arteaga, 2002; Barker et al., 2001).  
Treatments against EGFR are the most successful 
molecule-targeted drugs for cancer treatment. Pervious 
studies showed that the drug gefitinib (Iressa), which is 
an inhibitor of EGFR tyrosine kinase, has been shown to 
suppress activation of EGFR signaling for survival and 
proliferation in non-small cell lung cancer (NSCLC) cell 
lines.   Some   reports   have  demonstrated  rapid  down- 










regulation of ligand-induced EGFR in a gefitinib-sensitive 
cell line and inefficient down-regulation of EGFR in a 
gefitinib-resistant cell line during the exponential growth 
phase. This implies that each cell type employs a 
different down-regulation mechanism. However, the 
mechanisms of drug sensitivity to gefitinib remain unclear 
(Baselga et al., 2000; Arnoletti et al., 2004; Chang et al., 
2008; Sordella et al., 2004; Paez et al., 2004; Lynch et 
al., 2004).  
Although some drugs that inhibit EGFR have been 
used in the clinic, problems still remain. There is a need 
for more specific and sensitive methods to screen for 
drugs that target EGFR. 
The present study established a human wildtype-EGFR 
eukaryotic vector and obtained cell lines with stable and 
high-expression of EGFR. Results demonstrated that 
EGF media induced faster proliferation with increasing 
EGFR expression, most likely due to influences of the 
intracellular MAPK pathways. The A431 cell line, which 
expresses the wildtype EGFR gene, is a naturally 
occurring, high expressing EGFR cell line, which was 
compared with the prepared high-expression HEK293-
EGFR cell line. The gene sequence and encoding amino 
acids were basically identical and some of the biological 
characteristics were similar. Cellular membrane 
chromatography results, using the positive control drugs 
erlotinib, dasatinib, gefitinib, sorafenib, sunitinib, imatinnib 
and taspine, demonstrated that A431 improved specificity 
and sensitivity of target drug screening to EGFR. 
Accordingly, the A431 cell line could be a useful tool for 
targeted drug screening. 
 
 
MATERIALS AND METHODS 
 
Cell culture and reagents 
 
HEK293 cells, a kind gift from Professor Yuan Bingxiang (School of  
Medicine, Xian Jiaotong University), were maintained in DMEM 
(Gibco/Invitrogen, USA), supplemented with 10% fetal bovine serum 
(Hyclone, USA) and penicillin/streptomycin (Gibco/Invitrogen), and 
were incubated at 37°C in a 5% CO2 incubator with saturated 
humidity. The HEK293 and transformed EGFR cell lines were 
maintained in DMEM supplemented with G418 for screening and 
were incubated in identical conditions. 
A431 cells (human epidermoid carcinoma) were a kind gift from 
Professor Li Xu, who obtained them from the ATCC (American 
Type Culture Collection, USA). The cells were maintained in DMEM 
(Gibco/Invitrogen) supplemented with 10% fetal calf serum and 
were incubated at 37°C in a 5% CO2 incubator. 
The control drugs erlotinib, dasatinib, gefitinib, sorafenib, sunitinib 
and imatinib were purchased from AnGe Pharmaceutical Company, 
China and were diluted in fresh media prior to each experiment. 
The final DMSO concentration was < 0.1%. 
 
 
Construction of a EGFR eukaryotic expression vector 
 
The plasmid pBabe-Puro EGFR WT, which contains full-length 
EGFR cDNA, was a kind gift from Professor Heidi Greulich 
(Department of Medical Oncology, Oncology, Dana-Farber Cancer 
Institute, Boston, Massachusetts, USA). EGFR was amplified from 
a pBabe-Puro EGFR WT with PCR primers, 5’-CGGGGTACCA 
TGCGACCCTCCGGGAC-3’ and 5’-GCTCTAGATCATGCTCCAAT 
AAATTC-3’, (the underlined sequences contained restriction 
enzyme sites for KpnI and XbaI, respectively), and was digested 
with KpnI and XbaI. The thermocycling conditions were 35 cycles of 
denaturation at 98°C for 10 s, annealing at 55°C for 15 s and 
extension at 72°C for 4 min, followed by a final 5-min extension at 
72°C. The digested fragment was inserted into the same sites of 
pcDNA3.1 (+). The construction plasmid pcDNA3.1 (+)-EGFR was 
digested with BamH1 for detection (Figure 1). All sequences, with 
exception to two base pairs, were verified by DNA sequencing using 
the PRISM BigDye Terminator Sequencing Kit (Applied Biosystem 
Division, Perkin Elmer, Foster City, CA, USA) with wild-EGFR 
(Transcript variant 1). Furthermore, the sequences encoded the 
same amino acids as the wildtype EGFR transcript variant 1. 
 
 
Transfection and infection 
 
HEK293   cells   infected   with   EGFR   using  Lipofectamine  2000  




(Invitrogen) were plated on 24-well plates. After 24 h, a 1: 10 
dilution was transferred to new plates. Two days after infection, 
G418 (200, 400, 600 and 800 ng/mL, respectively), was added to 
screen for a suitable condition. At 7 – 10 days after screening, 600 
ng/mL was determined the most suitable condition. After 6 – 8 
weeks in culture with 600 ng/mL G418, the aft-HEK293 cells were 
selected and screened. Subsequently, a clonal cell line was derived 
and termed HEK293-EGFR. 
 
 
Cell cycle distribution by flow cytometric analysis of cell 
growth 
 
HEK293-EGFR, A431 and EGF-treated cells were harvested by 
trypsinization, washed with PBS and then fixed in 95% ethanol. 
Following removal of ethanol by centrifugation, cells were then 
incubated with phosphate-citric acid buffer [0.2 M Na2HPO4 (pH 
7.8)/4 mM citric acid] at room temperature for 45 min. After 
centrifugation, cells were then stained with a solution containing 33 
µg/mL propidium iodide (PI), 0.13 mg/mL RNase A, 10 mM EDTA 
and 0.5% Triton X-100 at 4°C for 24 h. Stained nuclei were analyzed 
for DNA-PI fluorescence using a Becton Dickinson FACScan flow 
cytometer. Resulting DNA distributions were analyzed by ModFit 
(Verity Software House Inc., Topsham, ME, USA) for the proportion 
of cells in G0/G1, S and G2-M cell cycle phases. 
 
 
FCM analysis of cell surface EGFR expression  
 
To analyze EGFR expression, 1 × 106 HEK293, HEK293-EGFR and 
A431 cells were resuspended in 200 µL PBS and incubated with 
fluorescein isothiocyanate-conjugated antibodies for 30 min at room 
temperature. EGFR monoclonal antibodies were used: (BD, 
PharMingen, San Diego, CA, USA). Following wash steps, the cells 
were analyzed with a flow cytometer. 
 
 
RT-PCR for detection of EGFR expression 
 
RNA from 1 × 107 cells was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) and reverse-transcribed according to the 
manufacturer’s instructions, (Invitrogen). EGFR full-length gene was 
amplified with primer pairs. The thermocycler conditions are 
described above.  
 
 
Western blot analysis   
 
Hek293, Hek293-EGFR and A431 cell lines were maintained in 
DMEM containing 10% fetal bovine serum (FBS) v/v. Prior to 
incubation with monoclonal antibodies, the cells were starved for 18 
h in DMEM supplemented with 1% FBS v/v. This low serum 
concentration was selected to reduce the amount of exogenous 
growth factors while ensuring cell survival, according to previously 
described methods (Fischel et al., 2005). Prior to growth factor 
stimulation, cells were incubated for four hours in serum-free 
medium (DMEM) with 10 ng/mL EGF, as previously described by 
Raben et al (1985). These three cell lines were incubated with 
gefitinib (0.5 µmol/L) for 4 h in serum-free medium (DMEM), 
followed by incubation with 10 ng/mL EGF. Membranes were 
incubated with the following antibodies: anti-phospho-EGFR 
residues (Tyr, 1197), anti-phospho-ERK 1/2 (Thr202/Tyr204), anti-
EGFR, (Cell Signaling Technology, Beverly, MA, USA). GAPDH 
served as the control protein for Western blot analysis. Following 
incubation with secondary antibodies, immunoblots were detected 
using the enhanced chemiluminescence (ECL) reagent (GE Health 
Care, SP, Brazil) and bands were quantified with Labworks, version 





Cellular membrane chromatography preparation and analysis 
 
HEK293-EGFR and A431 cells in log-phase growth were digested 
with trypsin. The cell suspension was centrifuged at 1000 × g/min 
for 10 min. The supernatant was removed. Sufficient hypotonic 
solution was added for 30 min and sonic oscillation was performed 
for 20 min, followed by centrifugation for 10 min at 1000 × g/min to 
remove cellular debris. The supernatant was centrifuged for 10 min 
at 12000 × g/min, and the remaining precipitate was the cell 
membrane. All above-mentioned steps were performed at 4°C. 
Activated silica was placed into a reaction tube and the cell 
membrane suspension solution was added to it. Adsorption of the 
cell membrane on the silica surface was activated by oscillation 
until equilibrium was reached, followed by centrifugation at 2000 
rpm to remove free cell membrane. The resulting solution served as 
the silica gel carrier cell membrane stationary phase (CMSP). 
CMSP was packed in the chromatography column and equilibrated 
with 50 mmolL–1/pH 7.4 PBS buffer as a mobile phase for 3 – 4 h at 
a column temperature of 37°C. The positive controls erlotinib, 
dasatinib, gefitinib, sorafenib, sunitinib and imatinib were added to 
the mobile phase for analysis and were detected by ultraviolet 220 
– 280 nm wavelength. Liquid chromatography constituted LC-






Construct a high-EGFR expression HEK293-EGFR 
cell line  
 
The target gene of human EGFR eukaryotic vector 
pcDNA3.1 (+)-EGFR was established in the present 
study and results from BamHI enzyme digestion are 
shown in Figure 1. The established vector was sequenced 
and compared with the gene bank of human EGFR 
transcript variant 1. Results demonstrated that both 
encoded amino acids were consistent (3637 base pairs 
were identical with exception of two bases). This did not 
affect EGFR functions, because the encoded amino acids 
of the eukaryotic vector pcDNA3.1 (+)-EGFR were not 
altered. Sequence data and amino acid encoding is not 
presented.  
To investigate expression of full-length EGFR mRNA in the 
HEK293-EGFR cell line, RT-PCR analysis was performed, 
as shown in Figure 2.  
According to flow cytometry results, EGFR expression 
was 4-5 times greater in the Aft-HEK293 cells following 
transfection. EGFR expression in the A431 cell lines is 
shown in Figure 3.  
 
 
A431 compared with HEK293-EGFR cell line  
 
According to the cell growth curve, there were no significant 
differences between HEK293 and HEK293-EGFR cells. 
However, A431 cells proliferated faster than HEK293 
cells. 
Immunofluorescence analysis was used to detect EGFR 
expression in Aft-HEK293 and A431 cells, revealing that A431 
cells strongly expressed EGFR (Figure 4). Subsequently, 
under EGF stimulus, cell cycle before  and  after  HEK293   






Figure 2. RT-PCR detection of EGFR mRNA in the HEK293-EGFR cell line. 
Lane 1 - HEK293-EGFR cell line; lane 2 - HEK293 cells; lane 3 - HEK293 with 






Figure 3. Detection of EGFR expression in various cell lines by flow cytometry. Cells were stained with anti-EGFR antibody. A: negative 
control; B: EGFR expression in A431 cell line; C: EGFR expression in fore-transfection HEK293 cell line; D: EGFR expression in aft-




transfection, as well as in the A431 cell line, was 
analyzed by flow cytometry. Results showed no 
difference between the groups (data not shown).  
Following EGF stimulation,  Western  blot  analysis  was 
used to screen fore-and-aft HEK293 and A431 cell lines 
for expression of EGFR, p-EGFR, and p-ERK. Gefitinib 
reduced phosphorylation of EGFR and Erk (Figure 5). 
Results   demonstrated   greater   EGFR    and    p-EGFR  
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expression in the aft-transfection HEK293 cells, which 
demonstrated higher bioactivity of transfected EGFR. 
HEK293 cells expressed high expression and the A431 
cells were thought to induce transcriptional up-regulation 
in the nucleus through the p-ERK pathway, resulting in 
cell proliferation. 
Flow cytometry results demonstrated that the cell cycle 
was inhibited by gefitinib in the above-mentioned cells 
lines. Western blot analyses showed that p-EGFR and p-
ERK expressions were also inhibited. These data further 
suggested that Hek293 and A431 cells exhibit similar 




EGFR-positive drugs detected using A431 cells by 
CMC  
 
Following rinsing with phosphate buffer saline (PBS) of 
the HEK293-EGFR and A431 cell lines, ultraviolet wave-
length detection by cell membrane chromatographic 
column was analyzed. Gefitinib was maintained on these 
two types of cell membrane and discharge curve behaved 
very similar. A431 retained longer on-peak chromato-
graphic and greater on-peak area (data not shown). The 
other EGFR positive drugs, erlotinib, dasatinib, gefitinib, 
sorafenib, sunitinib, imatinnib and taspine were also 
detected. Results showed these drugs had remaining 
peaks in the A431 cell membrane. These results demon-
strated that the A431 cell line could be used to screen 
drugs via cell membrane chromatographic analysis. 
Because EGFR was expressed at greater levels, the 










use of gefitinib, etc, several questions remain. The screening 
of anti-EGFR compounds from natural compounds could 
assist the generation of synthetic compounds. The 
present study utilized the naturally high-expressing wild-
type EGFR cell line (A431 cell line) and compared it to a 
stably, high-expressing HEK293-EGFR cells line. Results 
demonstrated 4 – 5 times higher expression following 
EGFR transfection. 
HEK 293 cells were generated by transformation of 
cultures of normal human embryonic kidney cells with 
sheared adenovirus 5 DNA in the laboratory of Alex Van 
der Eb in Leiden, Holland, in the early 1970s. Human 
embryonic kidney 293 cells, also referred to as HEK293, 
293 cells, or less precisely, HEK cells, are easy to grow, 
transfect very readily and have been widely used in cell 
biology research for many years. They are also used by 
the biotechnology industry to produce therapeutic 
proteins and viruses for gene therapy. 
In this study, the HEK293-EGFR cell line was esta-
blished. EGFR expression in the HEK293-EGFR cell line 
was high expression receptor on the HEK293-EGFR cell 
membrane than compared to other cell lines. This 
characteristic could be beneficial for screening EGFR-
targeted compounds. Previous studies indicated that 
A431 cells highly express EGFR (1.2 × 106 sites/cell) and 
largely depend on the EGFR/MAPK pathway for sustained 
proliferation (Janmaat et al., 2003; Meira et al., 2009). 
The A431 cell line is a human epithelioma cell line, with 
high expression of EGFR in the coding region (GenBank 
accession number NM-005228; GI-4885198). Two base 
pairs are different between the EGFR expressed in the 
A431 cell line and wildtype EGFR (1620C/G and 
2361G/A; GenBank, Transcript variant 1; NM-005228; GI-
41327737). In the 1620C/G variant, the asparagine (N) is 
substituted by lysine (K) and the extracellular region is 
composed of 621 amino acid residues. The site 1620C/G 
is located in the extracellular region and is a non-reactive 
binding site. However, there are no amino acid exchanges 
in the 2361G/A variant. The Hek293-EGFR cell line, 
which stably expressed high levels of EGFR, did not 
contain any encoding amino acids changes compared 
with wildtype EGFR (GenBank, Transcript variant 1; NM-
005228; GI-41327737).  
Flow cytometric and Western blot analyses were used 
to confirm the above-mentioned results. Transfected 
EGFR exhibited the same biological activity; EGFR, p-
EGFR and p-ERK expression increased with increasing 
EGFR gene expression in the cells. EGFR expression 
was induced by EGF and triggered bioactivity functions, 
which promoted proliferation and activated the MAPK 
signal pathway. 
The cell membrane receptor acts as the “start” signal 
for target cells to transfer signals along a pathway. The 
receptor recognizes the combination and interaction of 
particular characteristics on the corresponding receptor in 
the cytoplasm of the target cell, thereby activating 
biochemical changes in cells, or second messengers.  




The receptor also transfers signals into the nucleolus, 
which leads to gene expression changes and relevant 
biological effects. The cell surface receptor exhibits 
greater sensitivity to new drugs when its expression is 
high (Oh et al., 2004; Okuse et al., 2002). 
The A431 and HEK293-EGFR cell lines exhibited similar 
biological characteristics. Because the gene sequence 
and encoding amino acids were basically identical, the 
cell cycle and signal pathways were important factors of 
greater bioactivity with increasing EGFR expression. 
Moreover, the A431 cell line proliferated faster,  which  could 
be beneficial to cellular membrane chromatography pre-
paration and analysis. 
The two cell lines exhibited similarity with regard to 
gefitinib remaining in the cellular membrane chromato-
graphy analysis. Other drugs, such as erlotinib, dasatinib, 
gefitinib, sorafenib, sunitinib, imatinnib and taspine 
exhibited better maintained in the A431 cell membrane. 
The A431 cell line improved specificity and sensitivity for 
screening drugs targeted to EGFR, based on cellular 
membrane chroma-tography analysis. Because the A431 
cell line is a tumor cell line, it also expresses many other 
receptors at high levels. Other compounds could target 
A431 surface receptors. However, the HEK293-EGFR 
established cell line only expresses little receptors and 
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